Complement-targeted Therapeutics Market

Complement-targeted Therapeutics Market: Overview

Complement-targeted therapeutics are therapeutics that modulate the complement system. The complement-targeted therapeutics market has begun attracting clinical potential due to the observation that complement activation is a part of numerous inflammatory diseases. This lead to significant undesirable effects and infection risks for patients. Thus, the complement-targeted therapeutics market has begun attracting interest of drug developers for more than a decade now. In past couple of years, drug makers have been trying to develop complement inhibitors that can alleviate such effects. On way of doing this is by keeping the effect of drugs to specific anatomic sites.

Over the years, complement-mediated injuries has seen the approval of antibodies, propelling evolution of the complement-targeted therapeutics market. The current study on the market provides insights into the ongoing research and development activities and scenario planning for emerging drug pipeline. The report offers insights that will help incumbents as well new entrants identify the areas where they can tap into long-term market potential.

Complement-targeted Therapeutics Market: Key Trends

Expanding understanding of innate immune systems in humans is a key component of lucrative avenues in the complement-targeted therapeutics market. Growing number of tissue-targeting strategies for complement activation will shape development efforts of new therapeutics. In recent years, several drugs for site-targeted complement inhibitors have entered in the clinical stage. There is a need for pathophysiologic role of intracellular complement proteins that overcome the limitations of monoclonal antibodies and recombinant proteins that have been considered complement blockers. Over the past few years, growing clinical potential of complement-targeted therapeutics in periodontitis is boosting the growth in the market.

The drive for new array of complement inhibitory molecules is a key trend boosting the growth of the complement-targeted therapeutics market. Key diseases are hemolytic uremic syndrome (HUS) and paroxysmal nocturnal hemoglobinuria (PNH). There have been a number of therapeutics for site-targeted complement inhibition.

Complement-targeted Therapeutics Market: Competitive Analysis and Key Developments

Molecule developers have seen a high risk of infectious complications during complement inhibition, and thus bringing chronic complement inhibitor treatment a recurrent problem. This has led many drug developers to study systemic complement inhibition, intensifying the need for site-targeted complement inhibition. The need is also useful in modulating anti-tumor responses, concur researchers in the complement-targeted therapeutics market.

A number of assays help in understanding the pharmacodynamics of targeted complement inhibitors. The advent of non-invasive methods that can tissue complement deposits help in improving the biomarker utility for researchers in the complement-targeted therapeutics market. These have not been possible without bio-distribution studies. Top players are trying new strategies for antibody-targeted complement inhibitors. They are also pinning hopes on CR2-targeted drugs

Some of the key industry players in the complement-targeted therapeutics market are AbbVie Inc., Allergan, Pfizer, Merck, Alexion Pharmaceuticals, Novartis AG, and Creative Biolabs.

Complement-targeted Therapeutics Market: Regional Assessment

Tissue-targeted complement therapeutics play crucial role are attracting voluminous research spending in North America and Europe. Rise in investments in complement-directed drug discovery in these regions have led drug developers to change gears and tap into the emerging potential. Growing diversity of clinical disorders in Asia and the developed world are spurring new revenue prospects in such regional markets.

Growing number of drug candidates for chronic diseases in the U.S. has augmented the revenue potential of the complement-targeted therapeutics market. Government agencies in North America and Asia are seeing higher research contributions toward exploring the role of complement systems to the disease progress. The presence of numerous aspiring players in Europe has made this region as one of the rapidly expanding regional market.

Interested in this report?
Get a FREE Brochure now!

Request Brochure

*Get Brochure (PDF) sent to your email within minutes